|
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation |
Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Rogers G, Hoyle M, Thompson Coon J, Moxham T, Liu Z, Pitt M, Stein K. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technology Assessment 2012; 16(22): 1-410 Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Costs and Cost Analysis; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Thiazoles AccessionNumber 22012020303 Date bibliographic record published 13/06/2012 |
|
|
|